期刊文献+

盐酸伐昔洛韦的波谱学研究 被引量:3

Structure Elucidation of Valacyclovir Hydrochloride by NMR Spectroscopy and Mass Spectroscopy
下载PDF
导出
摘要 以嘌呤为原料合成盐酸伐昔洛韦(Valacyclovirhydrochloride),经乙酰化反应生成乙酰基嘌呤,水解后与侧链反应,钯碳存在下脱保护、成盐制得目标化合物.采用1HNMR、13CNMR、DEPT、1H1HCOSY、HMQC、HMBC和MS等技术确证目标化合物的分子结构;对其1HNMR、13CNMR信号进行了全归属,MS的主要裂解途径和离子特征也与伐昔洛韦的分子结构相符. Valacyclovir hydrochloride, 2-[ (2-amino-1, 6-dihydro-6-oxo- 9H-purine-9-yl) methoxy] ethyl-L-valinate hydrochloride, was synthesized from purine through acetylation, hydrolysis, condensation and deprotection reactions. The structure of the target compound was elucidated by combined use of mass spectroscopy and 1D/2D NMR techniques including ^1H and ^13C NMR, DEPT, ^1H-^1H COSY, HMQCand HMBC. The ^1H and ^13C chemical shifts of the compound were completely assigned.
出处 《波谱学杂志》 CAS CSCD 北大核心 2005年第3期309-314,共6页 Chinese Journal of Magnetic Resonance
关键词 NMR MS 归属 伐昔洛韦 NMR, mass spectroscopy, valacyclovir, chemical shift assignment
  • 相关文献

参考文献5

二级参考文献8

  • 1李正化.Pharmacochemistry(药物化学)(3rd. ed)[M].Bingjing:People′s Medical Publishing House,1993.152.
  • 2Tucker H. Non-Steroidal Anti-androgens in the Treatment of Prostate Cancer [J]. Drugs Future, 1990, 15(3): 255-265.
  • 3Lunglmayr G. The International Casodex Study Group. Efficacy and toterability of Casodex in patients with advanced prostate cancer [J]. Anti-cancer Drugs, 1995, 6(4): 508-513.
  • 4Sorbera L A, Rabasseda X, Castaner J, et al. Rosiglitazone Maleate [J]. Drugs Future, 1998, 23(9):977.
  • 5Boneu B, Destelle G. Platelet anti-aggregating activity and tolerance of Clopidogrel in atherosclerotic patients[J]. Thombosis and Haemositasis, 1996, 76(6): 939-943.
  • 6Mills D C B, Puri R, Hu C J, et al. Clopidogrel inhibits the binding of ADP analogues to the receptor mediating inhibition of platelet adenylate cyclase[J]. Arterioscler Thromb, 1992, 2: 430-436.
  • 7Salvi P, Heilmann E, Nurden P, et al. Clopidogrel: An antithrombotic drug acting on the ADP-dependent activation pathway of human platelets Clin[J]. Appl Thromb Haemost 1996, 2: 35-42.
  • 8Barrbie C Cantello, Michael A Cawthorne, Graham P Cottam, et al. [[ω-(Heterocyclylamino) alkoxy] benzyl]-2,4-thiozolidinediones as Potent Antihyperglycemic Agents [J]. Med Chem, 1994, 37(23): 3 977-3 985.

共引文献10

同被引文献7

  • 1刘力军,仲伯华,缪振春.胸腺五肽的NMR研究[J].波谱学杂志,2005,22(2):201-207. 被引量:9
  • 2刘力军,王林,李鲁,缪振春.新型H^+/K^+-ATP酶抑制剂泰妥拉唑的NMR测定分析[J].中国新药杂志,2006,15(1):47-49. 被引量:2
  • 3刘力军,缪振春,仲伯华,刘河,刘克良.一维NOESY和HOHAHA技术用于苯环壬酯的立体结构研究[J].波谱学杂志,2006,23(1):23-29. 被引量:5
  • 4KAKINOKI B, ONO C, YAMAZAKI N, et al. General pharmacological properties of the new proton pump inhibitor ( +/- )-5-methoxy-2-[ [ (4-methoxy-3,5-dimethylpyrid-2-yl) methyl] sulfinyl ] -1H-imidazo [ 4,5-b ] pyridine [ J ]. Methods Find Exp Clin Pharmacol, 1999, 21 (3) : 179 - 187.
  • 5GALMICHE JP, BRULEY DES VARANNES S, DUCROTTE P,et al. Tenatoprazole, a novel proton pump inhibitor with a prolonged plasma half-life : effects on intragastric pH and comparison with esomeprazole in healthy volunteers[J]. Aliment Pharmacol Ther, 2004,19 ( 6 ) :655 - 662.
  • 6PROUS J, MEALY N, CASTANER J. TU-199[J]. Drugs Fut,1994,19(11 ) :1018 - 1019.
  • 7Roupe K A, Helms G L, Halls S C, et al. Preparative enzymatic synthesis and HPLC analysis of rhapontigenin: applications to metabolism, pharmacokinetics and anti-cancer studies[J]. J Pharm Pharmaceut Sci, 2005, 8(3) : 374-386.

引证文献3

二级引证文献8

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部